According to a new report by UnivDatos, the PARP Inhibitors Market is projected to reach USD 13,835 million by 2032, expanding at a robust CAGR of 12.9% during the forecast period. PARP (Poly ADP-ribose Polymerase) inhibitors are a class of targeted cancer therapies that block the activity of PARP enzymes responsible for repairing single-strand DNA breaks. By inhibiting these enzymes, PARP...